Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach
Storey R, Alexander J, Wojdyla D, Mehran R, Vora A, Goodman S, Aronson R, Windecker S, Granger C, Lopes R. Choice of P2Y12 inhibitor and clinical outcomes in the AUGUSTUS study: support for an individualised approach. European Heart Journal 2020, 41: ehaa946.1450. DOI: 10.1093/ehjci/ehaa946.1450.Peer-Reviewed Original ResearchP2Y12 inhibitorsStent thrombosisClinical outcomesPatient's risk of bleedingST ratesTreated with clopidogrelRisk of bleedingDefinite/probable stent thrombosisAspirin cessationCRNM bleedingBleeding riskMedian ageRandomized patientsElective PCIBaseline characteristicsAtrial fibrillationBleeding rateP2Y12TicagrelorIschaemic eventsClopidogrelVKAIndividualised choicePatient riskPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply